Eastern and South-Eastern Asia vs Malaysia: Proportion of the target population who received the final dose of
Eastern and South-Eastern Asia
21.0%
in 2024
Malaysia
78.0%
in 2024
Eastern and South-Eastern Asia rank
26th
Malaysia rank
28th
Proportion of the target population who received the final dose of over time
- Eastern and South-Eastern Asia
- Malaysia
How they compare
Malaysia currently reports 78.0% against 21.0% in Eastern and South-Eastern Asia, a difference of 57.0%.
That makes Malaysia's figure about 3.7 times Eastern and South-Eastern Asia's.
The two have swapped places 2 times across 14 shared years of data; in 2011 it was Malaysia ahead.
Eastern and South-Eastern Asia ranks 26th and Malaysia ranks 28th of 35 groups.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eastern and South-Eastern Asia | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3.1% | 82.6% | 79.4% | Malaysia |
| 2020s | 8.8% | 48.2% | 39.4% | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Eastern and South-Eastern Asia or Malaysia?
- Malaysia, at 78.0% against 21.0% in Eastern and South-Eastern Asia as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Eastern and South-Eastern Asia and Malaysia?
- 57.0%, with Malaysia ahead.
- How many years of comparable data are there for Eastern and South-Eastern Asia and Malaysia?
- 14 years are reported by both, from 2011 to 2024.
- How do Eastern and South-Eastern Asia and Malaysia rank globally for proportion of the target population who received the final dose of?
- Eastern and South-Eastern Asia ranks 26th and Malaysia ranks 28th of 35 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.